A 2026 real-world study followed 120 refractory lupus nephritis patients treated with UC-MSCs. Cumulative renal response reached 56.7% at 12 months with low relapse rates and zero severe adverse events. Here’s what clinicians need to know.
A 36-month clinical trial showed zero adverse events and 57% pain reduction when stem cells were injected into torn rotator cuffs. Here’s what weekend warriors and recreational athletes need to know about MSC therapy for sports injuries.
Every workout floods your bloodstream with stem cells — your body’s own repair crew. Learn how exercise mobilizes regenerative cells and why it matters for aging and healing.
The MERIT phase 1 trial published in Cell Reports Medicine shows that intravenous UC-MSC therapy is safe in subacute ischemic stroke, with early NIHSS improvement signals. Here’s what clinicians need to know.
A 2026 meta-analysis of 15 RCTs shows MSCs cut acute GvHD incidence by 53% and chronic GvHD by 50%. A biomarker-guided trial identifies which transplant patients benefit most — and a cell-free exosome approach may be next.
Your body’s stem cell population drops dramatically after 40. Here’s what the science says about why we age — and how regenerative medicine is fighting back.
A technical review of 3D bioprinting for cartilage repair: thiolated bioinks, scaffold optimization, MSC chondrogenesis, and the path to clinical translation.
Learn how MSC therapy is offering real hope for liver cirrhosis patients — with data from the latest 2026 clinical trials and real patient outcomes at our Bangkok clinic.
A technical deep dive into MSC immunomodulation for autoimmune disease: Treg induction, macrophage polarization, and clinical evidence from the SMART-MS trial.
Chinese 
English 
Russian 
French